2026-01-18 - Analysis Report
**Eli Lilly and Co Financial Report**
=====================================

### 1. Return Rate Analysis

#### Comparison with S&P 500 (VOO)

|  | Cumulative Return | Divergence | Relative Divergence |
| --- | --- | --- | --- |
| LLY | 266.92% | 173.56 (233.30 - 59.74 = 173.56) | 76.58% (Relative divergence indicates current position in the maximum-minimum fluctuation range) |
| VOO | 93.36% |  |  |

LLY has outperformed VOO significantly with a higher cumulative return rate of 266.92% compared to 93.36%. The degree of divergence is 173.56.

#### CAGR, MDD, Alpha, Beta Analysis

| Year | CAGR | MDD | Alpha | Beta | Market Cap (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 37.0% | 14.3% | 33.0% | 0.7 | 103.7B |
| 2017-2019 | 36.0% | 14.7% | 19.0% | 0.7 | 117.8B |
| 2018-2020 | 30.0% | 20.9% | 10.0% | 0.7 | 151.4B |
| 2019-2021 | 49.0% | 20.9% | 5.0% | 0.7 | 247.6B |
| 2020-2022 | 59.0% | 20.9% | 60.0% | 0.7 | 328.0B |
| 2021-2023 | 116.0% | 18.0% | 115.0% | 0.5 | 522.6B |
| 2022-2024 | 123.0% | 27.0% | 104.0% | 0.6 | 692.1B |
| 2023-2025 | 183.0% | 29.9% | 121.0% | 0.7 | 963.4B |

### 2. Recent Stock Price Analysis

|  | Price |
| --- | --- |
| Close | $1,038.40 |
| 5-day SMA | $1,060.57 |
| 20-day SMA | $1,070.50 |
| 60-day SMA | $1,009.06 |
| Last market price | $1,038.40 |

The closing price is $1038.40. The 5-day SMA, 20-day SMA, and 60-day SMA are $1060.57, $1070.50, and $1009.06, respectively.

### 3. RSI, PPO, and Delta_Previous_Relative_Divergence Analysis

|  | RSI | PPO | Expected Return |
| --- | --- | --- | --- |
| RSI | 41.58 | -0.70 | 58.30% |
| Delta_Previous_Relative_Divergence | -7.30 | worsening |
| 7-day Rank change | -3 | rank down |
| 7-day Dynamic Expected Return change | 6.20 | improving |

The RSI is 41.58, and the PPO is -0.70. The Expected Return is 58.30%. The Delta_Previous_Relative_Divergence is worsening.

### 4. News & Significant Events

* [2026-01-16] Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - The Motley Fool (news.google.com)
* [2026-01-16] Buy The Dip In LLY Stock? - Forbes (news.google.com)
* [2026-01-14] Eli Lilly: Sell It And Buy Novo Nordisk Instead (NYSE:LLY) - Seeking Alpha (news.google.com)
* [2026-01-13] Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns - Yahoo Finance (news.google.com)
* [2026-01-16] LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Yahoo Finance (news.google.com)
* [2026-01-15] Stocks making the biggest moves midday: Morgan Stanley, Coinbase, Taiwan Semi, Eli Lilly & more - CNBC (news.google.com)

### 4-2. Analyst Opinions

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
- Opinions: 28
- Target Price (avg/high/low): 1110.79 / 1500.00 / 770.00

### 5. Earnings Analysis

| Date | EPS | Revenue |
| ---:|---:|---:|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

### 6. Financial Information = Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

### 6. Financial Information = Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

### 7. Comprehensive Analysis (Summary of previous items)

LLY has performed exceptionally well with a high cumulative return rate of 266.92%. The stock has a buy consensus and a target price of $1110.79. The RSI and PPO are 41.58 and -0.70, respectively. The Expected Return is 58.30%. The news and significant events suggest volatility, with mixed opinions from analysts. The quarterly financial information shows a high revenue and profit margin. The capital and profitability analysis shows a high ROE.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.